Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice article. Thanks Yahoo, but could ya name a few names next time. Sounds like us.
http://health.yahoo.net/news/s/ap/us_med_gene_therapy_leukemia
OUCH!
That would be a bone head pick. I bet they didn't see the DNDN smack down that brought down the entire sector?
Its why I get all the pick sites too, but never follow any! Good to know who is pumping. When they pump, You usualy can find a funding guy dumping. Remember MITI gave up shares for $10mm?
This was to carry over operating costs till 2013.
Then you get Dendreon's class action thrown into the mix.
Maybe the perfect storm for us. Yes a great reload at this price.
The class action in DNDN is about pie-in-the-sky return on $$ invested, not what the drug can do. Remember DNDN gave rise to this class of drugs.
Look what it did to my other, Aria? Killer bottom play.
For now long term, but depending on news flow and share price I'd also trade. Too many biotechs move quickly on news only to retrace. I believe MITI will be a long term success story.
Are you trading it or investing for the long-term?
yes...back in at 4.90.
Has this board DOA???????????
Money Morning [dot] com recommends strong buy on MITI to it's paid subscribers with 2000% possible gains.
When will Micromet cancer drug development deal with Amgen translate into PPS increase?
And is anyony hear?
So, why didn't this shoot up on the news?
So, why didn't this shoot up on the news?
Very encouraging article by Prohost Biotech.
http://seekingalpha.com/article/279488-the-sky-s-the-limit-for-micromet-s-bite-technology?source=nasdaq
and an earlier one from Hammer Stock Blog of July 3rd
Top 10 Oncology Drugs Available for Partnering (Pt. 2)
That puts about $15+MM directly into the operation coffers. When this stuff gets its IND, its off the charts. Amgen is smart, they have the rights to "Pick" three solid tumors they want indication to treat. That leavs many more indication left for others to come in and pick up another partnership.
Breats, colon, prostate are the big ones to treat. Then you have skin, eye, brain, most anywhere. Cancer really sucks. Got two in the family fighting this stuff today. Thats new since I first found MITI. One day! I pray.
Micromet Announces Solid Tumor BiTE Antibody Collaboration With Amgen
Biocompare
http://www.biocompare.com/News/NewsStory/384941/Micromet-Announces-Solid-Tumor-BiTE-Antibody-Collaboration-With-Amgen.html
Source: BUSINESS WIRE
Wednesday, July 13, 2011
• Collaboration on up to three targets and two programs
• Upfront payment of €10 million upon deal execution
• Maximum deal value of €695 million plus royalties and development cost reimbursement
ROCKVILLE, Md.--July 11, 2011--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.
“The BiTE antibody provides an innovative approach to cancer therapy,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “Amgen is pleased to collaborate with the Micromet scientific team to deploy this technology against targets for the treatment of solid tumors.”
Under the terms of the agreement, Amgen is expected to pay €10 million upon deal execution. If milestones in multiple indications and tumor types are achieved, Micromet is eligible to receive up to €342 million in clinical and commercial milestone payments. Micromet is also eligible to receive up to double-digit royalties on worldwide net sales.
For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties and development funding comparable to the first program. The combined potential payments to Micromet from both programs, excluding reimbursement of research and development costs, are approximately €695 million. The initial development plan contemplates €25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND. All expected costs associated with the research, development and commercialization of the BiTE antibodies will be borne by Amgen.
Micromet will be primarily responsible for the discovery and pre-clinical development of the BiTE antibodies. Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from the collaboration.
“We are very pleased to collaborate with Amgen, an industry leader with a proven track record of success in oncology and biologics,” said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. "This collaboration aligns well with our strategy to expand development of BiTE antibodies into solid tumor indications with support from a partner and brings important non-dilutive capital into the company."
About BiTE Antibodies
BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
Nice little 2 day run on killer news.
Its onlt projected as a $700MM deal in revenues. and that just one small aspect of the company.
Anyone think this run can make a third day?
Big news!
Just another partner in marketing.
HELLO!!!!!
MITI - Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen
http://ih.advfn.com/p.php?pid=nmona&article=48390064&symbol=MITI
Micromet, Inc. (NASDAQ: MITI) announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.
“The BiTE antibody provides an innovative approach to cancer therapy,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “Amgen is pleased to collaborate with the Micromet scientific team to deploy this technology against targets for the treatment of solid tumors.”
Under the terms of the agreement, Amgen is expected to pay €10 million upon deal execution. If milestones in multiple indications and tumor types are achieved, Micromet is eligible to receive up to €342 million in clinical and commercial milestone payments. Micromet is also eligible to receive up to double-digit royalties on worldwide net sales.
For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties and development funding comparable to the first program. The combined potential payments to Micromet from both programs, excluding reimbursement of research and development costs, are approximately €695 million. The initial development plan contemplates €25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND. All expected costs associated with the research, development and commercialization of the BiTE antibodies will be borne by Amgen.
Micromet will be primarily responsible for the discovery and pre-clinical development of the BiTE antibodies. Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from the collaboration.
“We are very pleased to collaborate with Amgen, an industry leader with a proven track record of success in oncology and biologics,” said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. "This collaboration aligns well with our strategy to expand development of BiTE antibodies into solid tumor indications with support from a partner and brings important non-dilutive capital into the company."
About BiTE Antibodies
BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and Sanofi. Additional information can be found at www.micromet.com.
Safe Harbor Statement
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the collaboration with Amgen, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibodies that are the subject of the agreement with Amgen, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, the initiation of a second BiTE program under the collaboration with Amgen and the future payment of upfront, milestone and royalty payments by Amgen. You are urged to consider statements that include the words "ongoing," "may," “eligible,” "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that our product candidates do not demonstrate safety and/or efficacy in pre-clinical studies or clinical trials, delays in development and testing, including the risk that Amgen will not obtain approval to market our product candidates and the risks associated with reliance on collaboration partners such as Amgen and outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC.
The big players are beginning to find Micromet's approach to tumour killing attractive and effective. They're starting to BITE (excuse the pun - Oh,OK! Don't).
Prospects are looking increasingly happy.
Postive news release just out.
http://phx.corporate-ir.net/phoenix.zhtml?c=197259&p=irol-newsArticle&ID=1583739&highlight=
whoa big end of day drop off. Prob nice gap up monday.
MITI - Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
http://ih.advfn.com/p.php?pid=nmona&article=48058933&symbol=MITI
Micromet, Inc. (NASDAQ: MITI) today announced the appointment of Ulrich Grau, Ph.D., as Executive Vice President, Chief Operating Officer, effective as of today.
Dr. Grau brings to Micromet more than 30 years of operations and R&D leadership experience in global biotechnology and pharmaceutical companies.
"We are delighted to welcome Uli to Micromet," said Christian Itin, Ph.D., Micromet's President and CEO. "Uli's global operations management experience and demonstrated track record of successful late-stage product development will be extremely valuable as we look to deliver on substantial clinical development and commercial goals for blinatumomab."
Dr. Grau most recently served as President and CEO of Lux Biosciences, Inc, a clinical stage private ophthalmic company that he co-founded. From 2002 to 2005, he served as Enzon’s Chief Scientific Officer and head of R&D. During his tenure at Enzon, he upgraded the company's R&D capabilities and built a portfolio of product candidates based on Enzon’s proprietary technologies and partnered programs. Prior to joining Enzon, Dr. Grau served as President of Research and Development and was a member of the Executive Board at BASF Pharma/Knoll where he directed a global R&D organization and significantly advanced and expanded the Company’s product portfolio, which included development of adalimumab (Humira®). Earlier in his career, Dr. Grau served as Senior Vice President and R&D integration officer of Aventis Pharma, and as Senior Vice President Global Product Realization at Hoechst Marion Roussel where he directed the company’s global late-stage product development activities.
Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab. You are urged to consider statements that include the words "will," "believes," "potential," "plans," "intends," “may,” “suggests,” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab does not demonstrate safety and/or efficacy in on-going or future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, filed with the SEC on March 9, 2011, Micromet's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC. Micromet cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Micromet also disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Blinatumomab has that strong smell of success!! I bought into Micromet in November when blinatumomab came over my horizon. I'm not a professional investor, only a retired paediatrician who for many years worked in a Paediatric Oncology Clinic in the UK in the 1960/70s. The drugs that were used then have hardly changed in today's practice, just one or two new ones essentially as toxic as the old ones and without a startling effect on the cure/survival rate. Yes, it can be fairly easy to get some neoplastic diseases like leukaemias into remission but keeping them there and into a 5-year off-drug survival rate is not easy for the patients (there are always some who die from the treatment rather than the disease) and can leave them with lifelong problems (reduced fertility and the threat of second treatment-induced neoplasms).
But with blinatumomab we are seeing a very different picture in acute lymphoblastic leukaemias.
Firstly, it doesn't seem to be all that toxic - some neurological problems which are reversible and now a cytokine-release problem which can be prevented now that it is known about.
Secondly, it works well where all other treatments have failed, putting roughly 75% of these patients into remission and, remember, it is just these patient's whose disease has defied all current therapy.
Thirdly, and to my mind, perhaps the most significant finding, the post-treatment remissions are very long-lived, just how long is not yet known since the first patients with leukaemia were treated and went into remission about a year ago. Compare that with conventional therapy where relapses in leukaemia off-therapy usually occur within weeks or a few months. This suggests that even after treatment has finished there is an on-going process which is either still suppressing the malignant clone of cells or the malignant clone has been totally eliminated by the 4 week course of therapy.
This final difference accords well with the underlying mechanism of the treatment which is just such a logical way of tackling the disease - identify a (relatively) unique surface marker on the malignant cell and build an antibody which will latch onto it AND onto a surface marker on a Killer T-cell so as to bring the two together. The clinical trials have so far proved the concept and no disasters have been produced. It even looks like the postulate is correct that the "activated" Killer T-cells have the capacity to develop into an ongoing clone of their own so as to "knock off" any of their target malignant cells which may have so far escaped or have developed anew long after the treatment with blinatumomab has been completed. Furthermore, there is no basic reason why this technology cannot be applied to any other malignancy as long as a fairly unique surface marker can be identified and a way found to get the antibody to the target malignancy.
IT ALL SMELLS SO RIGHT!! Forget the money for a moment but if this works, as I now have ever increasing confidence it will, I will be a very happy doctor!!
MITI up to $5.84 on positive data:
6:09AM Micromet will present data demonstrating co's Blinatumomab produces high single-agent activity in patients with relapsed acute lymphoblastic leukemia (MITI) 5.29 : Co announces that it will show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia who had relapsed following treatment with standard therapy. Interim results from this phase 2 single-arm trial showed that 75% of patients (9 of 12) achieved a complete remission or CR with partial recovery of blood counts following treatment with blinatumomab. All nine responding patients achieved a complete molecular response, or had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival. Notably, four patients with genetic abnormalities typically associated with poorer outcomes all achieved a CR or CRh. Co states: "These results are particularly striking relative to the fact that the majority of enrolled patients had characteristics typically associated with a dismal outlook."
Study Demonstrates Micromet’s Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblasti...
http://ih.advfn.com/p.php?pid=nmona&article=48019354&symbol=MITI
Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet’s blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.1 Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
Interim results from this phase 2 single-arm trial showed that 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh*) following treatment with blinatumomab. All nine responding patients achieved a complete molecular response, or had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival. Notably, four patients with genetic abnormalities typically associated with poorer outcomes all achieved a CR or CRh*.
“Relapsed/refractory acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades,” said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg and the chair of the study. “To date blinatumomab has shown an impressive and unprecedented level of efficacy in a patient population with limited therapeutic options."
The most common clinical adverse events were fever, peripheral edema and fatigue. Treatment of two of the twelve patients was interrupted due to fully reversible and manageable CNS events. In one patient, cytokine release syndrome was observed, which was mitigated in subsequent patients through dose modification and pre-treatment with concomitant medication. No additional cytokine release syndrome was observed.
“These results are particularly striking relative to the fact that the majority of enrolled patients had characteristics typically associated with a dismal outlook,” said Professor Topp.
Current treatment for Philadelphia negative relapsed/refractory ALL consists of combinations of toxic chemotherapy drugs that in the majority of cases fail to drive the disease into remission. In more than 30 years, no new drug has been approved for use in this setting, leaving physicians with few options to improve long-term patient outcomes other than variations in the dose and schedule of old drugs with limited efficacy. With current approaches, complete remission rates range from 17-45%.2-6 Standard chemotherapy is associated with a mortality rate of up to 23%.7 The average five-year survival rate for adult ALL patients after first relapse is 7%.5
Study design
This study is designed to evaluate the efficacy, safety and tolerability of blinatumomab in up to 25 adult patients with B-precursor ALL who relapsed after at least induction and consolidation treatment or who have refractory disease. Patients receive blinatumomab as a continuous infusion for 28 days followed by a treatment free interval of two weeks. Patients who achieve a CR/CRh* within the first two treatment cycles can receive consolidation with either three additional cycles of blinatumomab or allogeneic HSCT. The primary endpoint of the study is the rate of CR/CRh*. Secondary endpoints include molecular response rate, duration of response and overall survival. Enrollment in this study is currently on-going.
Conference Call and Webcast
Micromet management will host a conference call on Monday, June 13 at 8:00 AM EST to review the data presented at EHA. To participate in the conference call, please dial (877) 861-4516 (domestic) or (706) 902 - 4249 (international) and reference the conference ID 74624665. The presentation will be available via webcast at: www.micromet.com.
A replay of the call will be available from 9 AM ET on June 13, 2011 until midnight on July 4, 2011. To access the replay, please dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and reference the access code 74624665. The archived webcast will be available for 30 days in the Investor Relations section of the Micromet website at www.micromet.com.
About Blinatumomab
Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non Hodgkin's lymphomas. Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.
About Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia (ALL) is an aggressive cancer of the blood and bone marrow that afflicts 5,760 patients in the U.S. annually. Patients with ALL have abnormal white blood cells (lymphocytes) that crowd out healthy white and red blood cells and platelets, leading to infection, anemia (fatigue), easy bleeding and other serious effects.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab, the potential safety, efficacy and utility of blinatumomab, and the potential impact on the long-term survival of ALL patients treated with blinatumomab. You are urged to consider statements that include the words "will," "believes," "potential," "plans," "intends," “may,” “suggests,” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab does not demonstrate safety and/or efficacy in on-going or future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, filed with the SEC on March 9, 2011, Micromet's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC. Micromet cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Micromet also disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
References:
1. Topp, M.S. et. al. Haematologica. 2011; abstract no. 844
2. Kantarjian H, et al. Cancer. 2010;116:5568–5574.
3. Advani AS, et al. Br J Haematol. 2010;151(5):430.
4. Oriol A, et al. Haematologica. 2010;98(4):589-596.
5. Fielding A, et al. Blood. 2007;109(3):944-950.
6. O’Brien S, et al. Cancer. 2008;113:3186–3191.
7. Bassan R, et al. J Clin Oncol. 2011;29(5):532-543.
Looks like MrMarket doesn't like the shareholders conferances.
Anyone else think is a stall for more time or a need for more third party dilution?
Odd its going down. Happy I didn't get that $5.5 fill yesterday.
May take a stab @ the high $4's if its going down like this.
Yeulp $5.55 was a killer guess. I was off by a nickle today.
Dern!
Amen to that. And as for a mod, we don't need one. But thanks.
Its the two conferances I'm wish I knew more of what they will be discussing. At this price it has to be a benifit. Even if it trails lower, it can't go much lower. But I'll keep buying down.
Gotta get my first fill, LOL. Looks like it doesn't want to play with me today. I may be off by a nickle. $5.55 looks to have been a better price. Makes my $5.50 a killer score. Hence the margin play.
I don't like buying these types of stocks on margin. It hurts if it goes the wrong way.
BID getting hit pretty good today. Its been tough to get her down, but give it time.
I feel a score soon.
With two back to back shareholder updates either its a death nail or they have killer news. LOL! Ya gotta love these all or nothing Pharma plays?
Anyway updates are 2 days away. Time frame is short. May buy on margin at this point today or tomorrow.
Had a buy in @ 5.5 for some time now. Looks good for a score. Just hope the shareholders update is positive filled with great info.
Even if we dip down below 5, I don't think it will be for long. I'll start my buy in's at every quarter she drops from my initial.
Wish I had more of a feeling what the company will be talking about.
Shareholder's update is a must for me.
Looking good. Got my finger on the trigger today. then news. Maybe that will scare the price down another 10%. LOL
I was looking to see who would dip the most. ARIA is holding strong. MITI wins out. Ita a buy now, JMHO, and I nmean a buy for ME!
Company's management team will present a corporate overview at two upcoming investor conferences:
Goldman Sachs 32nd Annual Global Healthcare Conference Thursday, June 9, 8 AM PT Rancho Palos Verdes, CA
Jefferies 2011 Global Healthcare Conference Thursday, June 9, 1 PM ET New York, NY
The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcasts will also be available on the Company's website.
Below $6 is a reload area. Now how low will it go?
This $5.70 is looking like the new floor.
$I'm setting up for a few re-entries from here.
Micromet to Report Blinatumomab Data at June Medical Conferences
http://ih.advfn.com/p.php?pid=nmona&article=47786489&symbol=MITI
Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at two upcoming medical meetings:
European Hematology Association Annual Congress
June 9 - 12, 2011, London, UK
Abstract title: Clinical activity of the anti-CD19 BiTE blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase 2 study
Abstract number: 844
Presentation date and time: Saturday, June 11, 5:30 – 6:45 PM GMT
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany
A copy of the abstract can be found at: www.ehaweb.org/
11th International Congress on Malignant Lymphoma
June 15 – 18, 2011, Lugano, Switzerland
Abstract title: Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin’s lymphoma (NHL) including MCL and DLBCL
Abstract number: 068
Presentation date and time: Thursday, June 16, 2:45 – 3 PM CET
First author: Marie Elisabeth Goebeler, MD, University of Wuerzburg, Wuerzburg, Germany
A copy of the abstract will be posted to: www.lymphcon.ch/
About Blinatumomab
Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non Hodgkin's lymphomas.
Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
I'm just watching it now... don't know your answer. I've been busy elsewhere.
Karin- Still planning on getting back into MITI at some point.
Quick question about today's PR: Do you know if this is the same data that they are scheduled to present at the EHA Annual Congress June 10-12?
TIA. -ob
I thought we were closer to the FDA approval. But that last 10mm private placement should have been more of a sign she has more time. Cool with me, I'm tied up in ARIA and a handfull of pink plays at the moment. Gotta love those pinks. They never stop making the next best stink play! LOL I love em.
NO, ITS DOWN ! LOL
one day it will go up ... Murphys law.
Of 20 evaluable patients, 80% (16 out of 20) achieved a complete molecular response, all within the first cycle of treatment.
And the stock is still flat.
Data Published in Journal of Clinical Oncology Highlights Significant Activity of Micromet’s Blinatumomab in Patients with ...
http://ih.advfn.com/p.php?pid=nmona&article=47710547&symbol=MITI
Micromet, Inc. (Nasdaq: MITI) today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive (MRD) acute lymphoblastic leukemia (ALL) were published in the May 16th on-line edition of the Journal of Clinical Oncology (JCO). Results of the study demonstrated that blinatumomab produced durable remissions in front-line adult ALL patients at high risk of relapse. Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
“ALL patients with residual leukemic cells in the bone marrow following treatment with front-line chemotherapy have a 90% risk of relapse and a resulting poor long-term prognosis," said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg, and lead author of the publication. "Results from this study show that blinatumomab has the potential to fundamentally change the long-term outcome for this difficult-to-treat disease."
Phase 2 Study Design
The multi-center Phase 2 study evaluated the efficacy and safety of blinatumomab in adult patients with B precursor ALL. Enrolled patients had evidence of leukemic cells in the bone marrow following treatment with front-line chemotherapy, otherwise known as minimal residual disease (MRD). The primary endpoint of the study was molecular complete response, or elimination of MRD below detectable levels. Key secondary endpoints included time to hematological relapse, time to molecular relapse and overall incidence and severity of adverse events. Patients received 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle. Patients received up to seven treatment cycles.
Phase 2 Results
21 patients were treated in the study. Of 20 evaluable patients, 80% (16 out of 20) achieved a complete molecular response, all within the first cycle of treatment. A priori a 22% molecular response rate was expected. A subset of the patients in the study received an allogeneic hematopoetic stem cell transplant (HSCT), a procedure that typically carries a high risk of mortality. Notably, all transplanted patients were alive 100-days following the transplant.
"Historically stem cell transplantation is associated with a high mortality rate, approximately 25% in adult patients1,” said Professor Topp. "Data from this study highlights the potential for blinatumomab to improve the outcome of the transplant by improving the physical status of the patient and safely reducing the burden of disease before the transplant."
Overall, blinatumomab was well-tolerated. Most adverse events occurred early, were transient and reversible. The most common clinical adverse events (any grade) were fever, headache and chills. Two patients discontinued treatment due to fully reversible adverse events; a seizure and a syncope (temporary loss of consciousness), respectively.
“These data continue to validate our confidence in blinatumomab's potential as a promising new treatment option for patients with ALL and heighten our excitement in the broad-based development program now on-going in this disease setting," said Jan Fagerberg, M.D., Ph.D., Micromet’s Chief Medical Officer.
BLAST: European Pivotal Trial in MRD-Positive Adult ALL Patients
Based on results from the Phase 2 trial, in September 2010, the Company initiated a Phase 2 multi-center, single-arm study, also known as BLAST (Blinatumomab Adult ALL MRD Study of T cell engagement), intended to evaluate the efficacy, safety and tolerability of blinatumomab in up to 130 evaluable adult patients with B-precursor ALL with MRD after treatment with front-line chemotherapy. Patients will receive 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to four treatment cycles. The primary endpoint of the study is molecular complete response. Secondary endpoints include 18 month relapse-free survival rate (for non-transplanted patients) and mortality rate within 100 days after stem cell transplantation. Data from the trial, if positive, is intended to support a market authorization in Europe. The Company currently expects to complete patient enrollment by the end of 2012. Additional information regarding the BLAST study is available at www.micromet.com or the U.S. government's clinical trials database at www.clinicaltrials.gov.
About Blinatumomab
Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.
About Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is an aggressive cancer of the blood and bone marrow that afflicts 5,760 patients in the U.S. annually2. Patients with ALL have abnormal white blood cells (lymphocytes) that crowd out healthy white and red blood cells and platelets, leading to infection, anemia (fatigue), easy bleeding and other serious effects. The average five-year survival rate for adult ALL patients after first relapse is 7%3. The presence of leukemic cells in the bone marrow following treatment with front-line chemotherapy, also known as minimal residual disease (MRD), is a recognized negative prognostic factor for patients with ALL. There are currently no therapies approved for the treatment of MRD-positive ALL.
About Micromet
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Safe Harbor Statement
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the potential of blinatumomab as a treatment for patients with acute lymphoblastic leukemia and the scope and enrollment of ongoing clinical trials. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that our preclinical data is not confirmed in clinical trials with our product candidates. This factor and others are more fully discussed in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K, and Amendment No. 1 thereof, for the year ended December 31, 2010. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
References
1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2010. Available at: http://www.cibmtr.org
2. American Cancer Society. Cancer Facts and Figures 2009
3. Fielding A, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950.
LOL!.....I love em. They are fun, like going to a Casino. Fun money only, but that should never have to be said twice.
fink- I'm sure that QASP is a good company, with a great future, and selling at an unbelievable price. No need to send me any info about it.
For me, there's just one tiny, uncorrectable, insurmountable problem with it: I don't buy pinks.
Best of luck to you in all your investments.
Good move. They don't call these Bio techs for no reasons.
They have one big kill zone and this was so expected.
Now ARIA will break above $10.00 ands MITI will drift down til it hits it supports and atarts all over.
You'll be back below $5.00 because you know the story and one smart cookie.
Take a look at QASP. Don't be laughing, but look at the exchange DD that you must own QASP to get! My shamless spam for the month.
Best of luck to you too! ;)
I sold at the end of the day yesterday, $6.55 from $5.98 average.
Best of luck.
Micromet Reports First Quarter 2011 Financial Results and Highlights Near-Term Milestones
http://ih.advfn.com/p.php?pid=nmona&article=47603968&symbol=MITI
Still in but not a happy camper. Going to hold, hopefully we see a recovery next week.
Best of luck.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
196
|
Created
|
12/04/06
|
Type
|
Free
|
Moderators |
Micromet, Inc. (NASDAQ: MITI)
Company Information:
2110 Rutherford Road
Carlsbad, CA 92008
Phone: (760) 494-4200
CIK
0001131907
Micromet, Inc. (NASDAQ: MITI) is a biotechnology company focused on the research and development of novel biological products for the treatment and control of cancer, inflammation and autoimmune diseases. All of these indication areas are characterized by significant unmet medical needs.
Using its antibody technology platforms, Micromet´s goal is to create novel drugs that are highly specific, effective and well tolerated in patients. The Company currently has four candidates, adecatumumab (MT201), MT293 (TRC093), MT110 and blinatumomab (MT103), in clinical trials against major cancer indications, including metastatic breast cancer and relapsed non-Hodgkin's lymphoma (NHL). In addition, Micromet´s pipeline includes a number of preclinical drug candidates and several compounds at research stage. The Company has strategic collaborations or license agreements with Bayer-Schering, Sanofi-aventis, MedImmune, Merck Serono, Morphotek, Nycomed and TRACON Pharmaceuticals.
Management:
Christian Itin, PhD, President, Chief Executive Officer and Director
Barclay Phillips, Senior Vice President and Chief Financial Officer
Patrick A. Baeuerle, PhD, Professor for Immunology, Senior Vice President and Chief Scientific Officer
Jan Fagerberg, M.D., Senior Vice President and Chief Medical Officer
Jens Hennecke, PhD, Senior Vice President Business Development
Mark Reisenauer, Senior Vice President and Chief Commercial Officer
Matthias Alder, LL.M, Senior Vice President, General Counsel and Secretary
Presentation & Webcast Archive:
http://www.micromet.de/index.php?id=77
BiTE Antibody Platform:
http://www.micromet.de/index.php?id=31
Investor Calendar:
http://www.micromet.de/index.php?id=79
Recent News:
http://www.micromet.de/en/news/archiv.php
Filings:
Transfer Agent:
Share Structure:
68,985,005 Outstanding as of Nov 2, 2009
Need updated info here
Investor Relations:
info@micromet-inc.com
(240) 235-0250
Contact Information Investors:
Ines-Regina Buth (760) 494-4235 (US) +49 (0)89 895277 221 (Europe) ines.buth@micromet-inc.com
Media Europe: Evelyn Wolf +49 (0)89 895277 220 evelyn.wolf@micromet-inc.com
Media US: Susan Noonan (212) 966-3650 susan@sanoonan.com
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |